The failure rate exceeds the 1 percent benchmark set by the U.K.’s National Institute for Health and Clinical Excellence. As such, Smith & Nephew has updated the indications for the hip implants to restrict its use with the company’s Synergy stems and during revision procedures. In these cases, the hip implant’s failure rate drops to 1.07 percent, this is considered acceptable, according to the report.
The safety notice does not include a recall of any kind.
More Articles on Orthopedic Devices:
EOS imaging Announces First Installation in Asia
LDR Receives FDA Approval for Minimally Invasive Spinal Surgery Device
Curetis, Heraeus Medical Partner to Develop Test for Implant Infections
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.